Two Parkinson’s patients treated with AXO-Lenti-PD, an investigative gene therapy, in an ongoing clinical trial continue to show improvement 12 months later, Axovant, the therapy’s developer, said in a release.
These findings at one year after treatment are important because this timepoint allows for a better assessment of therapy durability, and a more assured differentiation between placebo effects and therapeutic response, the company added.
Your best adjunct therapy pick
Stem Cell therapy for PD
Light Therapy Clinical Trial
Is high dose thiamine therapy effective for people not taking levodopa?
Some words of encouragement 
